Erste Asset Management GmbH Buys New Shares in Roivant Sciences Ltd. (NASDAQ:ROIV)

Erste Asset Management GmbH bought a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 214,000 shares of the company's stock, valued at approximately $2,457,000.

A number of other institutional investors have also modified their holdings of the stock. Clearbridge Investments LLC raised its holdings in Roivant Sciences by 51.3% during the second quarter. Clearbridge Investments LLC now owns 1,860,536 shares of the company's stock worth $19,666,000 after purchasing an additional 630,712 shares in the last quarter. Cetera Advisors LLC purchased a new position in shares of Roivant Sciences during the 1st quarter worth approximately $758,000. Point72 Asset Management L.P. lifted its holdings in shares of Roivant Sciences by 40.1% in the 2nd quarter. Point72 Asset Management L.P. now owns 647,126 shares of the company's stock valued at $6,840,000 after buying an additional 185,226 shares during the period. Exchange Traded Concepts LLC purchased a new stake in shares of Roivant Sciences in the third quarter valued at approximately $2,267,000. Finally, SG Americas Securities LLC acquired a new position in Roivant Sciences during the second quarter worth $472,000. Institutional investors and hedge funds own 64.76% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Cantor Fitzgerald restated an "overweight" rating on shares of Roivant Sciences in a research report on Thursday, September 19th. Bank of America upped their target price on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a "neutral" rating in a research report on Wednesday, September 11th. Finally, HC Wainwright reiterated a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $17.93.

Roivant Sciences Price Performance

Shares of NASDAQ ROIV traded down $0.36 on Tuesday, hitting $12.12. The company's stock had a trading volume of 5,195,345 shares, compared to its average volume of 5,821,949. The stock has a 50 day moving average of $11.78 and a 200-day moving average of $11.39. Roivant Sciences Ltd. has a 12-month low of $9.48 and a 12-month high of $13.06. The company has a market capitalization of $8.82 billion, a price-to-earnings ratio of 2.15 and a beta of 1.25.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, COO Eric Venker sold 100,000 shares of the firm's stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $11.32, for a total transaction of $1,132,000.00. Following the sale, the chief operating officer now directly owns 606,525 shares of the company's stock, valued at $6,865,863. This trade represents a 14.15 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Financial Lp Qvt sold 876,000 shares of Roivant Sciences stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $11.82, for a total transaction of $10,354,320.00. Following the sale, the director now owns 22,179,358 shares of the company's stock, valued at approximately $262,160,011.56. This trade represents a 3.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 3,677,309 shares of company stock valued at $43,283,184. 7.90% of the stock is owned by corporate insiders.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.